港股異動 | 永悦科技漲5% 控股股東江蘇華英持股比例增至29.753%
格隆匯11月29日丨永悦科技(603879.SH)漲5.26%,報7.8元,總市值28億元。永悦科技11月29日發佈公吿,2021年11月28日,公司控股股東江蘇華英與持股5%以上非第一大股東傅文昌簽訂了《關於永悦科技股份有限公司股份轉讓協議》(以下簡稱“轉讓協議”),傅文昌擬將其持有的上市公司45,640,000股無限售流通股份以協議轉讓方式轉讓給江蘇華英。協議轉讓後,江蘇華英持有公司107,799,500股,佔公司總股本的29.7530%。本次協議轉讓不會觸發受讓方的要約收購義務。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.